DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$71.25
2.39 (3.47%)
▲
5d:
+3.79%
30d:
-3.0%
90d:
+14.24%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 29, 2026
25d
Smart Money Distribution
None View Scanner →
Strength: 7.5/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 1.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.03
Based on 11.5% avg growth
INTRINSIC VALUE TODAY
$78.87
9.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $71.25, which is considered fair relative to its 30-day fair value range of $69.60 to $74.86. The stock's valuation (Forward PE: 23.1) is in line with its historical norms (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This pessimistic expectation contrasts with the company's recent 92.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a downtrend. Immediate support is located at $67.30, while resistance sits at $73.69. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $85.24 (+19.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a downtrend. Immediate support is located at $67.30, while resistance sits at $73.69. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $85.24 (+19.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$69.60 -
$74.86
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading below Wall St target ($85.24)
Trading Range Analysis
30-Day Trading Range
$69.60 -
$74.86
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$67.30
Resistance Level
$73.69
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.11
Wall Street Target
$85.24
(+19.6%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
23.1 vs 24.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$70.18
(-2%)
2-Year Target
$69.13
(-3%)
3-Year Target
$68.09
(-4%)
3-Yr Target (if PE normalizes)
(PE: 23→24)
$71.00
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.1, Growth: 18.9%)
$119.74
(+68%)
Base:
(SPY PE: 21.8, Growth: 18.9%)
$112.83
(+58%)
Bear:
(PE: 18.5, Growth: 18.9%)
$95.90
(+35%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Trailing PE: 29.55 | Current EPS (TTM): $2.33
Bull Case
$100.21
(+41%)
Analyst growth 32.3%, PE expands to 32.5
Base Case
$91.10
(+28%)
Market implied 32.3%, PE stable at 29.6
Bear Case
$46.82
(-34%)
Severe decline -20.0%, PE contracts to 25.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.1 to 24.1
Stabilization Target:
$74.29
(+4.3%)
PE Expansion Potential:
+4.3%
Share & Embed Analysis
Last updated: July 03, 2026 6:05 PM ET
Data refreshes hourly during market hours. Next update: 7:05 PM
Data refreshes hourly during market hours. Next update: 7:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
